Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment.
Level 2 - randomized trial
Individual randomized controlled trial
PubMed 23690582 · doi:10.1073/pnas.1301816110
What was done
Elderly participants with mild cognitive impairment (according to 2004 Petersen criteria) were enrolled in a 2-year randomized controlled trial evaluating high-dose B-vitamin supplementation (0.8 mg folic acid, 20 mg vitamin B6, 0.5 mg vitamin B12) versus placebo. The authors evaluated changes in gray matter atrophy specifically in brain regions vulnerable to Alzheimer's disease (including the medial temporal lobe) and conducted causal Bayesian network analysis linking homocysteine changes, gray matter loss, and cognitive decline.
What was found
B-vitamin treatment reduced gray matter atrophy in Alzheimer-susceptible brain regions by up to seven-fold compared to placebo. In the placebo group, higher baseline homocysteine was associated with faster gray matter atrophy. The beneficial effect was confined to individuals with baseline homocysteine above the median (11 µmol/L). In this subgroup, network analysis supported a causal pathway wherein B vitamins lowered homocysteine, directly reducing gray matter atrophy and slowing cognitive decline. Absolute volumetric measurements, standard deviations, and exact p-values were not reported in the abstract.
Why it matters
This study shows that targeting elevated homocysteine via B-vitamin supplementation can slow structural brain atrophy in regions critical to Alzheimer's disease pathology. It identifies baseline homocysteine as a key biomarker determining therapeutic benefit in mild cognitive impairment.
Limits
The abstract does not disclose the sample size, dropout rates, exact volumetric numbers, or confidence intervals. The therapeutic effect was absent in participants with baseline homocysteine levels at or below 11 µmol/L, and the study evaluated surrogate neuroimaging and cognitive endpoints rather than clinical conversion to dementia.
Cited by
- partial Elevated homocysteine levels correlate with more rapid cerebral gray matter and hippocampal volume loss, and normalizing homocysteine halts this volume decline.